Mind Medicine Australia to Supply Psilocybin and MDMA at No Cost for New Innovative Clinical Trials
Mind Medicine Australia, 18 May, 2023
To further broaden the research base in Australia, MMA is delighted to announce that it will consider applications from research organisations to supply GMP medical grade psilocybin and GMP medical grade MDMA at no cost to support new clinical trials.
Leading Psychedelic Medicine Psychiatrist Coming to Australia
Mind Medicine Australia, 17 April, 2023
British Psychiatrist and Leading Psychedelic Medicine Specialist, Educator and Author – Dr Ben Sessa – to visit Australia, present Public Lectures and Lead the Residential Training for Students in Mind Medicine Australia’s Upcoming Certificate in Psychedelic-Assisted Therapies (CPAT) Course.
Announcement of Funding for Two New Research Projects to Test the Effects of Psychedelic Medicines for Obsessive Compulsive Disorder (OCD) and in Group Situations
Mind Medicine Australia, 20 March, 2023
Mind Medicine Australia is delighted to announce that it is funding two new research projects by the ANU School of Medicine and Psychology and a team led by Professor Paul Fitzgerald, Associate Professor Bernadette Fitzgibbon and Dr Neil Bailey, to broaden our understanding of the effectiveness and application of psychedelic medicines.
"Historic Supply Agreement Signed"
Globe News Wire, 01 March, 2023
Mind Medicine Australia enters into historic supply agreement with Canadian end-to-end GMP manufacturer, Optimi Health. Read the full media release from Optimi Health.
Major Announcements about Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies (CPAT)
Mind Medicine Australia, 28 February, 2023
Mind Medicine Australia Outlines its Next Steps for Psychedelic Assisted Therapies in Australia following the TGA’s Rescheduling Announcement for the Medical Use of Psilocybin and MDMA. In 2023 the program will be taken to a whole new level, with the engagement of an International Course Director Dr Gita Vaid MD (USA). In addition to this Dr Eli Kotler (AUS) has taken on the role of Australian Course Director and Dr Lauren Macdonald (UK) will also join the International Faculty.
Next Steps for Psychedelic Assisted Therapies in Australia following the TGA’s Rescheduling Announcement for the Medical Use of Psilocybin and MDMA
Mind Medicine Australia, 07 February, 2023
Mind Medicine Australia Outlines its Next Steps for Psychedelic Assisted Therapies in Australia following the TGA’s Rescheduling Announcement for the Medical Use of Psilocybin and MDMA
Breaking News: The TGA Announces the Delegate’s Final Decision to Reschedule the Use of Psilocybin and MDMA for Medical Purposes
Mind Medicine Australia, 03 February, 2023
Earlier today, the Therapeutic Goods Administration (TGA) announced that – from the 1st July 2023 – the medical use of MDMA and Psilocybin will be rescheduled from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. This will enable authorised psychiatrists to prescribe these substances for treatment-resistant depression and treatment resistant post-traumatic stress disorder.
An Urgent Opportunity to Help Fix Australia’s Broken Mental Health System by Supporting Psychedelic-Assisted Therapy
Mind Medicine Australia, 22 November, 2022
Australia’s mental health system is broken. Rates of mental illness and addiction are skyrocketing, leading to immense suffering and suicide in this nation. Even pre-Covid, Australia’s mental illness statistics were the second worst of all OECD nations, only ahead of Iceland!
This broken system has led to thousands of Australians with treatment-resistant mental illness. Franco Bortolin is a prime example of the reality for people with severe treatment-resistant mental illness.
An Open Letter To The Prime Minister
Mind Medicine Australia, 10 November, 2022
Vanessa Bortolin Delivers a Letter to the Prime Minister Anthony Albanese, Telling The Story of Her Husband’s Suicide and Requesting His Assistance In Creating A New Treatment Pathway For People With Treatment Resistant Depression By Allowing Limited Access To Psychedelic-Assisted Therapy.
She shared the tragic story of her husband, who lost his life to suicide after a 3-year battle with treatment-resistant depression, leaving behind his wife of 30 years, Vanessa, and their beloved daughter Zara.
Use of Psychedelic Therapies for Treatment Resistant Patients Again Rejected by Government, Despite Strong Supporting Safety and Efficacy Data, Massive Public Support and Australia’s Worsening Mental Health Crisis
Mind Medicine Australia, 28 October, 2022
Updated from 26 Oct. 22
Mind Medicine Australia (MMA) will prepare a detailed submission to the Therapeutic Goods Administration (TGA) following the Delegate’s “disappointing” decision not to include the limited medical use of MDMA and Psilocybin therapies in Schedule 8 of the Poison’s Standard, despite strongly supporting safety and efficacy results from overseas trials and strong controls.
World Renowned Professor David Nutt (UK) to visit Australia in November 2022 to build awareness of Psychedelic-Assisted Therapies
Mind Medicine Australia, 05 October, 2022
Mind Medicine Australia (MMA) is delighted to bring Professor David Nutt from Imperial College London to Australia to educate Australians about psychedelic-assisted therapies and endorse fair access to these life-saving treatments. His International Keynote is entitled ‘Psychedelic-Assisted Therapies: History, Neuroscience and Myths’.
Victorian Government Proposes Controversial Regulatory Change Amidst Worsening Mental Health Crisis
Mind Medicine Australia, 06 September, 2022
The Victorian Government has proposed a controversial change in health regulations to take away its current ability to issue permits for the clinical use of pharmaceutical grade MDMA and Psilocybin as part of psychotherapy for treatment resistant patients. MMA is one of several organisations and individuals that have lodged submissions outlining key reasons why the proposed regulatory change should not proceed.
Mind Medicine Australia announces a new fund to support the development of observational trials into psychedelic-assisted therapies in Australia for key classes of mental illness to better understand their translation into widespread clinical practice
Mind Medicine Australia, 23 August, 2022
Mind Medicine Australia (MMA) is excited to announce a new fund to support the development of observational trials into psychedelic-assisted therapies to treat a range of mental illnesses. The initial commitment of funding of $1 million will be provided by the Hunt Family Foundation with additional funding sought from other philanthropists.
Mind Medicine Australia, B’nai B’rith and Maccabi LIFE announce an exclusive screening of acclaimed Israeli documentary: Trip of Compassion
Mind Medicine Australia, 04 August, 2022
Mind Medicine Australia, in association with B’nai B’rith and Maccabi LIFE are thrilled to announce an exclusive screening of the highly acclaimed, Trip of Compassion on Sunday 28th August at 5pm, followed by a Q and A Panel, hosted by Mind Medicine Australia. This will be a collaborative social community event that will entertain, inform and educate.
Mind Medicine Australia announces an exclusive screening of acclaimed film: The Way of The Psychonaut in Byron Bay
Mind Medicine Australia, 01 August, 2022
Following the success of last year’s Fantastic Fungi screening, Mind Medicine Australia is thrilled to announce an exclusive screening of The Way of the Psychonaut: Stanislav Grof’s Journey of Consciousness, at Byron Bay Theatre on Thursday 25 August at 6:30pm followed by a Q and a Panel, hosted by Mind Medicine Australia’s Byron Bay Chapter.
Charity Mind Medicine Australia Totally Rejects Assertions made by ABC’s Four Corners program
Mind Medicine Australia, 26 July, 2022
Imagine a world where you or a member of your family is suffering with severe depression or PTSD and, in consultation with your medical practitioner, you can legally access safe, effective and affordable psychedelic-assisted therapy treatment in Australia. That is the mission of our charity, Mind Medicine Australia.
Decriminalisation in the ACT but still illegal to do TGA-approved psychedelic therapy
Mind Medicine Australia, 10 June, 2022
The ACT’s decriminalisation of illicit drugs showed the ACT had a government that was prepared to look at the facts but noted the contradiction that now exists between recreational usage of psychedelics and their clinical usage to treat chronic mental health conditions.
Ex-Chief of Defence Force urges ACT Government to allow medical use of psychedelic-assisted psychotherapy
Mind Medicine Australia, 02 June, 2022
Ex-Chief of the Defence Force, Admiral Chris Barrie AC, has urged the ACT Government to allow the medical use of psilocybin and MDMA assisted psychotherapies for patients suffering from treatment-resistant depression and treatment resistant post-traumatic stress disorder (PTSD).
Mind Medicine Australia welcomes consideration of changes to allow psychedelic therapy in the ACT
Mind Medicine Australia, 11 May, 2022
Mind Medicine Australia has welcomed consideration by the ACT Health Minister, Rachel Stephen-Smith, and the ACT Mental Health Minister, Emma Davidson, of legislative changes to allow psychedelic therapy in the ACT to treat mental illness.
Mind Medicine Australia Lodges New Applications for the Restricted Medical use of MDMA and Psilocybin Assisted Therapies for Patients with Treatment Resistant Mental Illnesses
Mind Medicine Australia, 17 March, 2022
Australia is experiencing a severe mental health epidemic, and this crisis is getting worse. Unfortunately, existing treatments only lead to remission for a minority of patients with depression and post-traumatic stress disorder and the psychiatric pharmaceuticals can cause dependence and nasty side effects for some patients. For this reason, Mind Medicine Australia is again seeking to reschedule the medical use of psilocybin and MDMA as part of therapy from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard.
Why is an Australian life less worthy than a Canadian’s?
Mind Medicine Australia, 09 February, 2022
Both Canada and Australia are battling a growing shadow pandemic of mental illness. Despite having world leading health care systems, both nations are facing an ever-increasing wave of mental illness, addictions and lives lost to suicide. On 4th January 2022, Health Canada announced that it will provide a pathway for physicians to obtain approvals for patients to access Psychedelic-Assisted Therapies through their Special Access Program. Australia has yet to implement a similar scheme.
New Polling by Mind Medicine Australia Reveals Over 60% of Australians Support Increased Access to Psychedelic Medicines
Mind Medicine Australia, 07 February, 2022
Mind Medicine Australia (MMA) is delighted to announce the findings of a sentiment poll we initiated through Essential Research last week.
Mind Medicine Australia joins global coalition launched to secure a rescheduling of psilocybin under the 1971 UN Convention on Psychotropic Substances
Mind Medicine Australia, 13 January, 2022
Today Mind Medicine Australia joins in the launch of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI), a global coalition working to promote and secure a rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances.
Emyria to expand Real World Data assets for MDMA-assisted therapy trials by incorporating wearables monitoring
Emyria (ASX: EMD ) Press Release, 20 December, 2021, 15 December, 2021
Emyria’s phase 2b MDMA-assisted therapy trial for severe Post Traumatic Stress Disorder (PTSD), EMDMA-001, developed with registered charity Mind Medicine Australia (MMA), will be the first program to incorporate Cydelic technology and is expected to be one of the first programs in the world to incorporate remote patient monitoring within MDMA-assisted therapy.
TGA says NO again to psychedelic-assisted therapies.
Mind Medicine Australia, 15 December, 2021
Mind Medicine Australia’s Response to the Announcement of the TGA NOT to Reschedule the Medical Use of MDMA for Treatment Resistant PTSD and the Medical Use of Psilocybin for Treatment Resistant Depression as Part of Therapy.
Monash University announces establishment of the Neuromedicines Discovery Centre to Focus on Psychedelic-Assisted Therapies for the Treatment of Key Classes of Mental Illness
Mind Medicine Australia, 10 November, 2021
We are delighted that Monash University has announced the establishment of the Neuromedicines Discovery Centre (NDC) to focus on psychedelic-assisted therapies for the treatment of mental illness. This initiative was developed from a proposal put to Monash University by Mind Medicine Australia and our advocacy work with key stakeholders.
Mind Medicine Australia Launches Australia’s First Book of Psychedelic Healing Stories
Mind Medicine Australia, 18 October, 2021
Mind Medicine Australia (MMA) is releasing a new book sharing the psychedelic healing stories of 53 Australians, in their own words. Launched during Mental Health Month, this first Australian book of true stories further reinforces the life-changing and life-saving impact of psychedelic-assisted therapies for a range of mental illnesses and addictions.
Launching a Dedicated Training, Education and Clinical Services Organisation Focusing on Psychedelic Assisted Therapies for Mental Illness and the Developing Understanding of the Mind, Cognition and Human Consciousness
Mind Medicine Australia, 12 October, 2021
Mind Medicine Australia (MMA) and Integrated Psychology and Medicine (IPM) are delighted to announce the establishment of a new training, education and clinical services organisation called Mind Medicine Training and Education (MMTE).
Expert Review Findings Support the Therapeutic Use of Medicinal Psychedelics in Treating Mental Health Crisis
Mind Medicine Australia, 03 October, 2021
The findings of an expert panel reviewing the use of psychedelics in treating Australia’s mental health crisis, give strong support to such treatments being introduced at this stage on a case-by-case basis, under the supervision of the patient’s doctors and trained therapists.
TGA moves one step closer to rescheduling MDMA and Psilocybin in Australia
Mind Medicine Australia, 01 October, 2021
Yesterday, the TGA released the Independent Review that it had commissioned on the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of key mental health disorders.
Mind Medicine Australia to host Australia’s Inaugural International Summit on Psychedelic Therapies for Mental Illness online in November 2021
Mind Medicine Australia, 02 September, 2021
Mental health charity Mind Medicine Australia (MMA) is delighted to announce the inaugural International Summit on Psychedelic Therapies for Mental Illness and 2-day Introductory Workshop will take place between 17–20 November 2021 online.
Australia’s crisis of suffering accelerates while effective treatment remains blocked
Mind Medicine Australia, 25 August, 2021
Mind Medicine Australia is urgently calling for the Federal and State governments to enable psychedelic-assisted therapies to be used to treat severely ill patients who desperately need safe and effective treatments.
TGA appoints Independent Expert Panel on MDMA and psilocybin
TGA, 05 August, 2021
The Therapeutic Goods Administration (TGA) Scheduling Delegate (decision maker) has deferred the final decision on applications to down-schedule MDMA and psilocybin from schedule 9 (prohibited drug) to schedule 8 (controlled drug) pending a review into the therapeutic value, risks and benefits to public health outcomes for these substances. The Independent Expert Panel to undertake this review has now been established.
Mind Medicine Australia announces 10 scholarships to be made available to outstanding female health professionals from the Northern Rivers Region
Mind Medicine Australia, 23 June, 2021
Mind Medicine Australia is delighted to announce that it will offer 10 scholarships for its Certificate in Psychedelic-Assisted Therapies (CPAT) for female psychiatrists, GPs, physicians, nurses, psychologists, psychotherapists, social workers, counsellors and occupational therapists in the Northern Rivers Shire of NSW.
Legislative changes to allow psychedelic-assisted therapy treatments for mental illness patients in the ACT if first approved by the TGA
Mind Medicine Australia, 15 June, 2021
Mind Medicine Australia has proposed conservative legislative changes to allow psychedelic-assisted therapy to be used for the treatment of mental illness in the ACT where they have first been approved by the Therapeutic Goods Administration (TGA).
The Enormous “Elephant in the Room” in assessing the Government’s Budget Announcement of a $2.3 billion increase to Mental Health Funding
Mind Medicine Australia, 13 May, 2021
Mind Medicine Australia (MMA) welcomes the Government’s commitment to mental health and its drive to improve the mental health of Australians and reduce suicide rates. The increased funding for the sector announced in the Budget is an especially important part of this.
Emyria and Mind Medicine Australia to launch Psychedelic-Assisted Therapy Program (EMDMA-001) for PTSD
Mind Medicine Australia, 10 May, 2021
On Wednesday 5 May, Emyria (ASX:EMD) and Mind Medicine Australia announced their first psychedelic-assisted therapy care program (EMDMA-001) for sufferers of treatment resistant post-traumatic stress disorder (PTSD).
TGA Seeks Independent Review on Rescheduling of Psilocybin and MDMA as Part of Therapy in Medically Controlled Environments
Mind Medicine Australia, 08 April, 2021
The TGA announced that the Scheduling Delegate has decided to seek further advice in relation to Mind Medicine Australia’s applications to reschedule psilocybin and MDMA as part of therapy in medically controlled environments.
Your Psychedelic Healing Stories Can Help Change and Save Lives
Mind Medicine Australia, 24 March, 2021
We’re putting together a special book about psychedelics in Australia, the first of its kind – filled with incredible and inspirational stories of people who’ve changed their lives through psychedelic medicines like psilocybin and MDMA.
Australia's Federal system blocking psychedelic treatments for mental illness
Mind Medicine Australia, 17 March, 2021
Mind Medicine Australia welcomes the Government’s announcement to provide $15 million for the development of innovative therapies for mental illness.
Mind Medicine Australia urges TGA to reverse its Interim Decision on scientific and humanitarian grounds
Mind Medicine Australia, 10 March, 2021
Mind Medicine Australia has just made its final submissions to the TGA opposing their interim decision NOT to reschedule psilocybin and MDMA as Controlled Medicines. A comparison with other substances listed in Schedule 8 of the Poisons Standard indicates that this is the right schedule for the medical use of these substances in controlled medical environments.
Mind Medicine Australia Announces Second Screening of Acclaimed Film Fantastic Fungi in Byron Bay
Mind Medicine Australia, 08 March, 2021
Mind Medicine Australia is thrilled to announce our second screening of Fantastic Fungi at 6:30pm on Tuesday March 30th at Byron Theatre in Byron Bay followed by a Q & A Panel and conversation. This is a second screening as the first screening has sold out.
Mind Medicine Australia Announces First Ever Event In Canberra – Screening of the World Acclaimed Film Trip of Compassion
Mind Medicine Australia, 19 February, 2021
Mind Medicine Australia is thrilled to announce our first ever screening of Trip of Compassion at 6:30pm on Wednesday March 3rd at Palace Electric Cinema in Canberra followed by a Q&A Panel and discussion.
Mind Medicine Australia challenges TGA Interim Decision
Mind Medicine Australia, 17 February, 2021
Mind Medicine Australia urgently needs your support to ensure the Rescheduling Applications for the Medicinal Use of Psilocybin and MDMA are approved by the Government in Canberra.
Mind Medicine Australia Prepares to Contest TGA’s Interim Decision Not to Reschedule Psilocybin and MDMA for Medical Use as Part of Therapy for Key Mental Illnesses
Mind Medicine Australia, 03 February, 2021
Mind Medicine Australia prepares to contest TGA’s interim decision not to reschedule psilocybin and MDMA for medical use as part of therapy for key mental illnesses.
Mind Medicine Australia Anticipates Interim Decision Regarding Australia’s First Applications to Reschedule Psilocybin and MDMA for Medical Use as Part of Therapy for Key Mental Illnesses to be Announced on February 3
Mind Medicine Australia, 12 January, 2021
Mind Medicine Australia awaits the Therapeutic Goods Administration’s (TGA) interim decision on the rescheduling of psilocybin and MDMA to be used as part of clinical therapy for the treatment of major classes of mental illness. If approved, this would reclassify the medicines from Schedule 9 (Prohibited Substance) of the Standard for the Uniform Scheduling of Medicines and Poisons, to Schedule 8 (Controlled Medicine).
World Famous Author & Physician Dr Gabor Mate Joins Global and Australian Leaders on MMA Advisory Board
Mind Medicine Australia, 02 December, 2020
World Famous Author & Physician Dr Gabor Mate Joins More Than 55 Global and Australian Leaders on Mind Medicine Australia’s Advisory Board. Dr Gabor Mate joins a diverse group of global and Australian leaders including Anthropologist Dr Wade Davis CM (Canada), Islamic Scholar and Imam Mohammad Tawhidi, Founder and Director of the Beckley institute Amanda Feilding (UK), Psychedelics researcher Dr Robin Carhart-Harris (UK), Psychiatrist Tanveer Ahmed, Human Rights Lawyer Scott Leckie and many others.
ASX Media Release: Emyria partners with Mind Medicine Australia to develop national care program and data registry for psychedelic-assisted therapies
ASX, 19 November, 2020
Mind Medicine Australia partners with Emyria (ASX: EMD) to develop national care program and data registry for psychedelic-assisted therapies.
Australian charity paving the way in psychedelic-assisted therapy launches FREE online webinar series during Mental Health Month
Mind Medicine Australia, 12 October, 2020
World-leading experts are brought straight into Australia’s living rooms for discussion about the ground breaking opportunity psychedelic-assisted therapies offer us, and the solutions needed to address problems caused by long-term reliance on pharmaceuticals for mental health treatment.
Mind Medicine Australia Shines a Light on Breakthrough Therapies for Mental Health this Mental Health Month
Mind Medicine Australia, 08 October, 2020
Mind Medicine Australia Shines a Light on Breakthrough Therapies for Mental Health this Mental Health Month.
Covid-19 Significant Societal and Mental Health Impacts Highlights Urgent Need for Innovation in Treatments for Mental Illness
Mind Medicine Australia, 30 September, 2020
Mind Medicine Australia exists to help alleviate the suffering caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients. We already had a major mental health epidemic prior to this pandemic, and this is being severely exacerbated as noted. New treatments are urgently needed to heal those who have and are being damaged by this major crisis.
Mind Medicine Australia Submits Australian-First Application for the Rescheduling of Psilocybin and MDMA
Mind Medicine Australia, 01 September, 2020
Mind Medicine Australia has submitted Australia’s first applications to the Therapeutic Goods Administration (TGA) to reschedule Psilocybin and MDMAso that they can be more easily used as part of clinical therapies for the treatment of major classes of mental illness.
ACT Support for Breakthrough Psychedelic-assisted Mental Health Therapies in Upcoming Election
Mind Medicine Australia, 01 August, 2020
Mind Medicine Australia welcomes the announcement of the ACT Greens in supporting the development of psychedelic-assisted therapies for the treatment of mental illness in its recently announced drug law reform policy platform.
Mind Medicine Australia Announces First in Southern Hemisphere - Certificate in Psychedelic-Assisted Therapies
Mind Medicine Australia, 01 June, 2020
Mental health charity Mind Medicine Australia (MMA) has announced the, first of its kind in the southern hemisphere, Certificate in Psychedelic-Assisted Therapies (CPAT).
Mind Medicine Australia calls for URGENT Mental Health Innovation Taskforce to tackle the mental health pandemic sparked by Covid-19
Mind Medicine Australia, 06 April, 2020
Mental health charity Mind Medicine Australia (MMA) calls for and strongly supports all recommendations to form a Mental Health Innovation Taskforce to be immediately established in order to guide the government in planning the next steps to manage the increasing mental health pandemic triggered by Covid-19 and the recent bushfires tragedy.
Urgent Need to Establish a Government-Appointed Steering Group to Fast-Track Consideration of Medicine-Assisted Psychotherapies in Australia
Mind Medicine Australia, 24 February, 2020
Mind Medicine Australia (MMA), an Australian-registered charity established to support the development of research-backed and regulatory-approved medicine-assisted psychotherapy in Australia, has publicly released its written submission to the Australian Productivity Commission (APC) in relation to its current inquiry into mental health. The document can be read on the APC Commission website here.
Mind Medicine Australia celebrates its First Anniversary
Mind Medicine Australia, 12 February, 2020
Today, Mind Medicine Australia turns one year old! In our first year, we have made remarkable progress in growing public awareness of Medicine-Assisted Therapy in Australia. We are already seeing a paradigm shift in the curiosity, acceptance, and interest into the use of medicine-assisted therapy for depression, addiction, PTSD, obsessive-compulsive disorder, anorexia and other challenges in our communities.
MDMA-assisted psychotherapy for bushfire victims - Fast-tracked access needed for breakthrough PTSD treatment
Mind Medicine Australia, 30 January, 2020
It is estimated that 800,000 Australians suffer from post-traumatic stress disorder (PTSD). Mental health experts predict this staggering figure will rise sharply as a result of the trauma experienced by families and first responders who have had their lives or safety threatened by the catastrophic bushfires this summer.
Premiere Melbourne Screenings - Fantastic Fungi
Mind Medicine Australia, 13 January, 2020
Mind Medicine Australia is proud to the present the Melbourne premiere of Fantastic Fungi. An exploration of Mycelium that is the very foundation of life on this planet – not only for our species but for so many species on this Earth that we love and we can work with it to restore our planet.
Premiere Byron Bay Screening - Trip of Compassion
Mind Medicine Australia, 06 January, 2020
Mind Medicine Australia is thrilled to announce a screening of the acclaimed documentary Trip of Compassion in Byron Bay, NSW.
Mind Medicine Australia announces new appointment to Board of Directors
Non-Executive Director, Mind Medicine Australia, 21 November, 2019
The Hon Andrew Robb announces his appointment to the Board of Mind Medicine Australia.
Launch Media Release: Almost one in two Australians will be affected by mental illness in their lifetime
Mind Medicine Australia, 01 February, 2019
Psychedelic Medicines Could Provide an Effective and Ground-Breaking Treatment, says Mind Medicine Australia.